Madinance (Chlormadinone Acetate, Ethinylestradiol)

Madinance, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal regulation of reproduction.

• Prevention of pregnancy: provides reliable contraceptive protection when taken as prescribed.
• Regulation of menstrual cycles: helps achieve more predictable bleeding patterns in women with irregular cycles.
• Management of dysmenorrhea: reduces menstrual pain and flow in women using hormonal contraception.

• Madinance combines chlormadinone acetate, a progestogen, with ethinylestradiol, an estrogen, to bind progesterone and estrogen receptors in the hypothalamic‑pituitary‑ovarian axis. This suppresses gonadotropin‑releasing hormone, luteinizing hormone, and follicle‑stimulating hormone secretion, preventing follicular development and ovulation. The progestogenic component also thickens cervical mucus and alters the endometrium, creating an environment hostile to fertilisation and implantation.

Madinance may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Breast tenderness: discomfort or swelling of the breasts.
• Headache: intermittent mild to moderate pain.
• Spotting or breakthrough bleeding: irregular light bleeding.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or mood swings.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Arterial thrombosis: clot formation in arteries leading to stroke or heart attack.
• Hypertension: elevated blood pressure requiring medical attention.
• Severe liver dysfunction: jaundice or abnormal liver enzymes.
• Anaphylactic reaction: rare severe allergic response requiring emergency care.

Before prescribing Madinance, clinicians should consider several safety aspects.

• Contraindicated in pregnancy: product is classified as pregnancy category X and must not be used.
• Avoid in smokers over 35 years: increased risk of cardiovascular events.
• Screen for thromboembolic risk: assess personal or family history of clotting disorders.
• Monitor blood pressure: hormonal components may elevate blood pressure.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Madinance can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong enzyme inducers (e.g., rifampin, carbamazepine): may markedly reduce contraceptive efficacy.
• Other estrogen‑containing products (e.g., hormone therapy): increase risk of thromboembolic events.

Moderate Interactions (Monitor Closely)

• Antifungal azoles (e.g., ketoconazole): may increase plasma levels of ethinylestradiol.
• Certain anticonvulsants (e.g., phenytoin): may alter hormone metabolism.
• Antiretroviral agents (e.g., protease inhibitors): may affect hormone concentrations.